vs
Aurinia Pharmaceuticals Inc.（AUPH）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
Aurinia Pharmaceuticals Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.0倍（$77.1M vs $75.5M），Aurinia Pharmaceuticals Inc.同比增速更快（28.8% vs 27.7%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 23.8%）
Aurinia Pharmaceuticals是一家生物制药企业，专注于自身免疫疾病及肾脏疾病靶向疗法的研发与商业化，核心获批产品为用于治疗成人活动性狼疮性肾炎的Lupkynis，主要市场覆盖北美及欧洲地区。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
AUPH vs PBYI — 直观对比
营收规模更大
AUPH
是对方的1.0倍
$75.5M
营收增速更快
AUPH
高出1.1%
27.7%
两年增速更快
PBYI
近两年复合增速
23.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.1M | $75.5M |
| 净利润 | $210.8M | — |
| 毛利率 | 88.6% | 69.3% |
| 营业利润率 | 43.1% | 22.7% |
| 净利率 | 273.4% | — |
| 营收同比 | 28.8% | 27.7% |
| 净利润同比 | 14651.2% | — |
| 每股收益（稀释后） | $1.52 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AUPHPBYI
| Q4 25 | $77.1M | $75.5M | ||
| Q3 25 | $73.5M | $54.5M | ||
| Q2 25 | $70.0M | $52.4M | ||
| Q1 25 | $62.5M | $46.0M | ||
| Q4 24 | $59.9M | $59.1M | ||
| Q3 24 | $67.8M | $80.5M | ||
| Q2 24 | $57.2M | $47.1M | ||
| Q1 24 | $50.3M | $43.8M |
净利润AUPHPBYI
| Q4 25 | $210.8M | — | ||
| Q3 25 | $31.6M | $8.8M | ||
| Q2 25 | $21.5M | $5.9M | ||
| Q1 25 | $23.3M | $3.0M | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $14.3M | $20.3M | ||
| Q2 24 | $722.0K | $-4.5M | ||
| Q1 24 | $-10.7M | $-4.8M |
毛利率AUPHPBYI
| Q4 25 | 88.6% | 69.3% | ||
| Q3 25 | 88.9% | 77.7% | ||
| Q2 25 | 89.8% | 76.5% | ||
| Q1 25 | 86.3% | 77.1% | ||
| Q4 24 | 90.7% | 76.4% | ||
| Q3 24 | 91.1% | 63.9% | ||
| Q2 24 | 84.4% | 77.4% | ||
| Q1 24 | 84.6% | 75.5% |
营业利润率AUPHPBYI
| Q4 25 | 43.1% | 22.7% | ||
| Q3 25 | 40.5% | 17.6% | ||
| Q2 25 | 28.7% | 12.7% | ||
| Q1 25 | 35.0% | 8.7% | ||
| Q4 24 | -2.8% | 22.6% | ||
| Q3 24 | 17.3% | 27.4% | ||
| Q2 24 | -2.6% | -4.6% | ||
| Q1 24 | -26.3% | -5.3% |
净利率AUPHPBYI
| Q4 25 | 273.4% | — | ||
| Q3 25 | 42.9% | 16.2% | ||
| Q2 25 | 30.7% | 11.2% | ||
| Q1 25 | 37.4% | 6.5% | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 21.2% | 25.2% | ||
| Q2 24 | 1.3% | -9.6% | ||
| Q1 24 | -21.4% | -11.0% |
每股收益（稀释后）AUPHPBYI
| Q4 25 | $1.52 | $0.26 | ||
| Q3 25 | $0.23 | $0.17 | ||
| Q2 25 | $0.16 | $0.12 | ||
| Q1 25 | $0.16 | $0.06 | ||
| Q4 24 | $0.00 | $0.40 | ||
| Q3 24 | $0.10 | $0.41 | ||
| Q2 24 | $0.01 | $-0.09 | ||
| Q1 24 | $-0.07 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.2M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $581.3M | $130.3M |
| 总资产 | $751.6M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资AUPHPBYI
| Q4 25 | $80.2M | $97.5M | ||
| Q3 25 | $72.9M | $94.4M | ||
| Q2 25 | $52.9M | $96.0M | ||
| Q1 25 | $66.1M | $93.2M | ||
| Q4 24 | $83.4M | $101.0M | ||
| Q3 24 | $36.6M | $96.7M | ||
| Q2 24 | $33.3M | $96.8M | ||
| Q1 24 | $63.9M | $107.2M |
总债务AUPHPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益AUPHPBYI
| Q4 25 | $581.3M | $130.3M | ||
| Q3 25 | $365.8M | $115.3M | ||
| Q2 25 | $335.3M | $104.7M | ||
| Q1 25 | $350.2M | $97.1M | ||
| Q4 24 | $377.5M | $92.1M | ||
| Q3 24 | $388.0M | $71.1M | ||
| Q2 24 | $364.6M | $48.5M | ||
| Q1 24 | $359.5M | $51.0M |
总资产AUPHPBYI
| Q4 25 | $751.6M | $216.3M | ||
| Q3 25 | $527.5M | $202.9M | ||
| Q2 25 | $502.6M | $194.9M | ||
| Q1 25 | $504.9M | $196.2M | ||
| Q4 24 | $550.6M | $213.3M | ||
| Q3 24 | $549.4M | $220.7M | ||
| Q2 24 | $523.5M | $205.0M | ||
| Q1 24 | $516.6M | $214.1M |
负债/权益比AUPHPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.7M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 0.22× | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流AUPHPBYI
| Q4 25 | $45.7M | $14.4M | ||
| Q3 25 | $44.4M | $9.7M | ||
| Q2 25 | $44.2M | $14.1M | ||
| Q1 25 | $1.3M | $3.6M | ||
| Q4 24 | $30.1M | $15.6M | ||
| Q3 24 | $17.0M | $11.0M | ||
| Q2 24 | $15.8M | $1.0M | ||
| Q1 24 | $-18.6M | $11.2M |
自由现金流AUPHPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
自由现金流率AUPHPBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
资本支出强度AUPHPBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率AUPHPBYI
| Q4 25 | 0.22× | — | ||
| Q3 25 | 1.41× | 1.10× | ||
| Q2 25 | 2.06× | 2.41× | ||
| Q1 25 | 0.06× | 1.21× | ||
| Q4 24 | 21.07× | — | ||
| Q3 24 | 1.19× | 0.54× | ||
| Q2 24 | 21.94× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AUPH
| Products | $74.2M | 96% |
| License Collaboration And Royalty Revenue | $2.9M | 4% |
PBYI
暂无分部数据
